{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:10:04Z","timestamp":1791943804976,"version":"4.3.4"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      Gallium\u201068 (\n                      <jats:sup>68<\/jats:sup>\n                      Ga) prostate\u2010specific membrane antigen (PSMA) ([\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga\u2010PSMA\u201011) directed PET\/CT reflects PSMA expression at metastatic sites and can hence be a surrogate of lutetium\u2010177 (\n                      <jats:sup>177<\/jats:sup>\n                      Lu) PSMA ([\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu\u2010PSMA) radiation delivery. This retrospective analysis aims to explore the association between quantitative baseline [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga\u2010PSMA\u201011 PET imaging biomarkers and treatment outcomes in our Asian cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We included patients with progressive metastatic castrate\u2010resistant prostate cancer (mCRPC) who received [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu\u2010PSMA radioligand therapy at our institution. The association between baseline [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga\u2010PSMA\u201011 PET parameters (SUVmax, SUVmean, total tumor volume [PSMA\u2010TV], total lesion uptake [PSMA\u2010TLU = PSMA\u2010TV \u00d7 SUVmean], and total lesion quotient [PSMA\u2010TLQ = PSMA\u2010TV \/ SUVmean]) and overall survival (OS), prostate specific antigen (PSA) progression free survival (PFS), PSA response, and toxicity were analyzed using univariate analysis. Optimal cut\u2010points were also explored.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between May 9, 2018 and October 7, 2024, 71 of 84 screened patients were eligible. The median whole\u2010body SUVmean in our cohort was 8.04. Higher PSMA\u2010TLQ and PSMA\u2010TV (per 10\u2010unit increment) were associated with shorter OS (HR 1.005; HR 1.005) and shorter PSA PFS (HR 1.005; HR 1.004). A higher PSMA\u2010TLQ was also associated with poorer odds of PSA response (OR 0.994). Conversely, higher SUVmean was associated with longer PSA PFS (HR 0.911) and improved odds of PSA response (OR 1.34). Higher PSMA\u2010TV (per 10\u2010unit increment) and PSMA\u2010TLU (per 100\u2010unit increment) were associated with increased hematological toxicity (OR 1.008; OR 1.012).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      PSMA\u2010TLQ and PSMA\u2010TV were negative prognostic markers and SUVmean was a positive prognostic marker among Asian patients with mCRPC who received [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu\u2010PSMA radioligand therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajco.14174","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T23:40:08Z","timestamp":1745451608000},"page":"399-406","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic [\n                    <sup>68<\/sup>\n                    Ga]Ga\u2010PSMA\u201011 PET Biomarkers for [\n                    <sup>177<\/sup>\n                    Lu]Lu\u2010PSMA Radioligand Therapy in Metastatic Castrate\u2010Resistant Prostate Cancer (Asian Population Study)"],"prefix":"10.1111","volume":"21","author":[{"given":"Nicola Xin Yi","family":"Koh","sequence":"first","affiliation":[{"name":"Department of Internal Medicine SingHealth  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Ming","family":"Chua","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging Division of Radiological Sciences Singapore General Hospital  Singapore Singapore"},{"name":"Department of Neuroradiology Division of Radiological Sciences Singapore General Hospital  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie Wing\u2010Chuen","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging Division of Radiological Sciences Singapore General Hospital  Singapore Singapore"},{"name":"Radiological Sciences Academic Clinical Program SingHealth Duke\u2010NUS Academic Medical Centre  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron Kian\u2010Ti","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging Division of Radiological Sciences Singapore General Hospital  Singapore Singapore"},{"name":"Radiological Sciences Academic Clinical Program SingHealth Duke\u2010NUS Academic Medical Centre  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindran","family":"Kanesvaran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology National Cancer Centre  Singapore Singapore"},{"name":"Duke\u2010NUS Graduate Medical School  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin Seng Cheong","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010Oncology National University Cancer Institute  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology Singapore General Hospital  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue Ping","family":"Thang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging Division of Radiological Sciences Singapore General Hospital  Singapore Singapore"},{"name":"Radiological Sciences Academic Clinical Program SingHealth Duke\u2010NUS Academic Medical Centre  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010022\u201006089\u2010w"},{"issue":"1","key":"e_1_2_8_3_1","first-page":"81","article-title":"Prostate\u2010Specific Membrane Antigen Expression in Normal and Malignant Human Tissues","volume":"3","author":"Silver D. A.","year":"1997","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12253\u2010008\u20109104\u20102"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10661"},{"issue":"17","key":"e_1_2_8_6_1","first-page":"6357","article-title":"Correlation of Primary Tumor Prostate\u2010Specific Membrane Antigen Expression With Disease Recurrence in Prostate Cancer","volume":"9","author":"Ross J. S.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)00237\u20103"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)01653\u20102"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(22)00605\u20102"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.09.014"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010020\u201004723\u2010z"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24518"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000004222"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12149\u2010022\u201001739\u20103"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010020\u201005040\u20101"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122938"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13944"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001179"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224055"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100044\u20101779634"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(23)00529\u20106"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.10.4923"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1118\/1.3499298"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e318279ffdf"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.sult.2010.10.001"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267014"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266842"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13550\u2010022\u201000891\u20101"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13550\u2010021\u201000805\u20107"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010021\u201005383\u20103"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.14174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T09:44:19Z","timestamp":1754905459000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.14174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/ajco.14174"],"URL":"https:\/\/doi.org\/10.1111\/ajco.14174","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"2025-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}